Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/1097-0142(197404)33:4<959::aid-cncr2820330410>3.0.co;2-v | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum miRNA-101 expression signature as non-invasive diagnostic biomarker for Hepatitis C virus-associated hepatocellular carcinoma in Egyptian patients.
Sci Rep
January 2025
Botany and Microbiology Department, Faculty of Science, Al-Azhar University, Cairo, 11884, Egypt.
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally due to HCC late diagnosis and limited treatment options. MiRNAs (miRNAs) emerged as potential biomarkers for various diseases, including HCC. However, the value of miRNA-101 as a serum biomarker for HCV-induced HCC has not been fully investigated.
View Article and Find Full Text PDFARID4B Promotes the Progression of Hepatocellular Carcinoma Through the PI3K/AKT Pathway.
Ann Surg Oncol
January 2025
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Background: AT-rich interaction domain 4B (ARID4B) is a transcriptional activator that regulates the phosphatidylinositol 3-kinase (PI3K)/AKT pathway in prostate cancer. However, the role of ARID4B in hepatocellular carcinoma (HCC) has remained unclear.
Methods: This study included 162 patients who had undergone primary hepatic resection for HCC between 2008 and 2019.
Diagnostic value of TAP, PIVKA-II, and AFP in hepatocellular carcinoma and their prognostic value for patients treated with transarterial chemoembolization.
Lab Med
January 2025
Department of Clinical Laboratory, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
Objective: The diagnosis and prognosis of hepatocellular carcinoma (HCC) present significant challenges in clinical practice. This study aimed to evaluate the clinical utility of tumor abnormal protein (TAP), Prothrombin induced by vitamin K absence-II (PIVKA-II), and alpha-fetoprotein (AFP) in diagnosing HCC as well as to investigate their prognostic significance in patients with HCC undergoing transarterial chemoembolization.
Methods: A total of 93 HCC patients were enrolled and 101 healthy individuals served as controls.
Ascorbic acid-immobilized zinc selenide for electrochemical monitoring of hydrogen peroxide in liver cancer samples.
Sci Rep
January 2025
Department of Biochemistry, Bahauddin Zakariya University, Multan, 60800, Pakistan.
Liver cancer is globally the most frequent fatal malignancy, and its identification is critical for making clinical decisions about treatment options. Pathological diagnostics and contemporary imaging technologies provide insufficient information for tumor identification. Hydrogen peroxide (HO), an emerging biomarker is a powerful oxidant found in the tumor microenvironment, and stimulates the invasion, proliferation, and metastasis of liver cancer cells.
View Article and Find Full Text PDFTreatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Anticancer Res
January 2025
Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Background/aim: Atezolizumab plus bevacizumab (AteBev) is widely used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, evidence regarding the optimal drug sequence following AteBev treatment is limited. This study aimed to compare the treatment outcomes between tyrosine kinase inhibitors (TKIs) and durvalumab plus tremelimumab (DurTre) following AteBev treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!